VivoSeq
Other

POI

0

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

POI is an early-stage landscape with 0 programs across 3 companies. The most active players are Novartis, Merck & Co., Aurobindo Pharma Ltd.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalA

Aurobindo Pharma Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed12 · 75%
Unknown status2 · 13%
Withdrawn1 · 6%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

Intrathecal Double Checkpoint Inhibition
Active, not recruiting·UUniversity of Zurich·Phase 1·NCT05598853·26 enrolled
Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension
Completed·AActavis Inc.·Phase 3·NCT03499873·448 enrolled
An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints
Completed·Novartis logoNovartis·Phase 2·NCT01216085·10 enrolled
A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
Completed·AActavis Inc.·Phase 3·NCT03954444·1,105 enrolled
Endpoint Validation Study (0524A-015)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT00533676·165 enrolled
A Pharmacovigilance Study of Torsade de Pointes
Completed·UUniversity of Peshawar·N/A·NCT04293432·6,670 enrolled
The Effect and Safety of the Four Points Transversus Abdominis Plane Block
Completed·GGia Dinh People Hospital·N/A·NCT03598192·30 enrolled
Topical Nitrates for Myofascial Trigger Points
Completed·GGF Strong Rehabilitation Centre·N/A·NCT01675700·10 enrolled
Clinical Benefit of Topoisomerase Downregulation
Completed·NNew Mexico Cancer Research Alliance·Phase 1·NCT00250094·15 enrolled
Clinical Endpoint Study of Ivermectin 0.5% Lotion
Completed·AActavis Inc.·Phase 3·NCT03301649·905 enrolled
TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant
Completed·PPETHEMA Foundation·Phase 2·NCT00386412·132 enrolled
Pre-POINT-Early Study
Completed·TTechnical University of Munich·Phase 2·NCT02547519·44 enrolled
Clinical Endpoint Study of Ivermectin 1% Cream
Completed·AActavis Inc.·Phase 3·NCT02840461·630 enrolled
Clinical Endpoint Bioequivalence Study of Adapalene Gel 0.1%
Withdrawn·AAurobindo Pharma Ltd·Phase 3·NCT04329403
ANRS CO24 OncoVIHAC (Onco VIH Anti Checkpoint)
Unknown status·AANRS, Emerging Infectious Diseases·N/A·NCT03354936·50 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)